BAFNAPH · Health Care · 2026-08-21

Bafna Pharmaceuticals Ltd

6.1★ FairStrong +6.9Stage 2 · wk 11In scan: Pullback Hunter · Prop Scan · Breakout WatchMARKET: BULL RISING · 2026-08-21
₹242.5
+2.00% today
₹574 Cr · Small cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences LLP.

Visit company website →
P/E (TTM)
31.8
Forward —
Earnings Growth (YoY)
+95.0%
Revenue +15.4%
vs 52W High
-14.9%
₹95.6 lo₹285 hi
14.9% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 11
1w13w26w
Week 11 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
52.9%
200 DMA: ₹158.6 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.89x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
MA20 trending up · +6.0% vs MA50 +25.1%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #3 of 84 Stage 2 stocks in Health Care by RS. Leading the sector.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #3 of 58 Stage 2 stocks in this industry. Top tier.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-26 → 2026-08-21
S4 17w
S4 20w
S2 22w
2023-05-262026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 1w → S1 3w → S2 7w → S3 5w → S4 12w → S1 5w → S2 6w → S3 1w → S4 11w → S1 6w → S4 11w → S1 2w → S4 17w → S1 4w → S4 20w → S1 2w → S2 22w → S3 12w → S4 5w → S1 7w → S2 11w current
Total tracked: 167 weeks across 21 stage runs.
1M
-0.2%
3M
+79.6%
6M
+103.3%
YTD
+48.3%
1Y
+168.1%
Scan Membership
Pullback Hunter
Latest: 2026-08-21
Prop Scan
Latest: 2026-08-21
Breakout Watch
Latest: 2026-06-09
47 appearances in last 60 days. First seen: 2024-01-19.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 11 · Vol —x
2026-08-20S2
Wk 11 · Vol —x
2026-08-19S2
Wk 11 · Vol —x
2026-08-18S2
Wk 10 · Vol —x
2026-08-17S2
Wk 10 · Vol —x
2026-08-14S2
Wk 10 · Vol —x
2026-08-13S2
Wk 10 · Vol —x
2026-08-12S2
Wk 10 · Vol —x
2026-08-11S2
Wk 9 · Vol —x
2026-08-10S2
Wk 9 · Vol —x
2026-08-07S2
Wk 9 · Vol —x
2026-08-06S2
Wk 9 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹225.3
200 DMA
₹158.6
52W High
₹285
52W Low
₹95.6
5D Low
₹237.7
Resistance levels (recent highs)
20d High
₹285
60d High
₹285
120d High
₹285
250d High
₹285
Next resistance
+17.6%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.